Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy
Objectives: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in non-small cell lung cancer (NSCLC) treatment. We investigated absolute eosinophil count (AEC) as a predictor of clinical outcomes and toxicity in NSCLC patients receiving ICIs. Materials and Methods: AEC was retrospectiv...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222000934 |
| _version_ | 1818495192802525184 |
|---|---|
| author | Enrico Caliman Sara Fancelli Carlotta Ottanelli Francesca Mazzoni Luca Paglialunga Daniele Lavacchi Marta Rita Gatta Michelet Elisa Giommoni Brunella Napolitano Federico Scolari Luca Voltolini Camilla Eva Comin Serena Pillozzi Lorenzo Antonuzzo |
| author_facet | Enrico Caliman Sara Fancelli Carlotta Ottanelli Francesca Mazzoni Luca Paglialunga Daniele Lavacchi Marta Rita Gatta Michelet Elisa Giommoni Brunella Napolitano Federico Scolari Luca Voltolini Camilla Eva Comin Serena Pillozzi Lorenzo Antonuzzo |
| author_sort | Enrico Caliman |
| collection | DOAJ |
| description | Objectives: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in non-small cell lung cancer (NSCLC) treatment. We investigated absolute eosinophil count (AEC) as a predictor of clinical outcomes and toxicity in NSCLC patients receiving ICIs. Materials and Methods: AEC was retrospectively collected at baseline and during treatment from 158 advanced NSCLC patients treated with single agent anti-PD1/anti-PDL1 monoclonal antibody in first or subsequent line of therapy at Medical Oncology Unit, Careggi University Hospital, Florence (Italy), between January 2016 to October 2020. Results: We found a significant association between high baseline AEC (≥130/μL) and better clinical outcomes. The response rates were 64.4% and 35.6% for patients with high and low AEC, respectively (p = 0.009). The high-AEC group showed a significantly longer PFS and OS than the low-AEC group (mPFS = 7.0 months, 95% CI 5.0–10.0 vs 2.5 months, 95% CI 2.0–4.0, p = 0.007 and mOS = 9.0 months, CI 95% 7.0–15.0 vs 5.5 months, 95% CI 4.0–8.0, p = 0.009, respectively). An increased risk of immune-related adverse events (irAEs) was reported in the high-AEC group (p = 0.133). IrAEs resulted an independent prognostic factor for both better outcomes (mPFS = 8.0 months, 95% CI 7.0–12.0 vs 2.0 months, 95% CI 2.0–3.0, p<0.001; mOS = 13.0 months 95% CI 9.0–19.0 vs 4.0 months 95% CI 3.0–6–0, p<0.001) and response to ICIs (response rate = 33.8% vs 14.9%, disease control rate = 72.0% vs 32.1%, p<0.001). Conclusion: High baseline AEC value (≥130/μL) is a predictive biomarker of clinical benefit and irAEs occurrence in NSCLC patients treated with ICIs. |
| first_indexed | 2024-12-10T18:17:14Z |
| format | Article |
| id | doaj.art-3cf480d4b5104565bd9fc6d9c01b622d |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-10T18:17:14Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-3cf480d4b5104565bd9fc6d9c01b622d2022-12-22T01:38:18ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0132100603Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapyEnrico Caliman0Sara Fancelli1Carlotta Ottanelli2Francesca Mazzoni3Luca Paglialunga4Daniele Lavacchi5Marta Rita Gatta Michelet6Elisa Giommoni7Brunella Napolitano8Federico Scolari9Luca Voltolini10Camilla Eva Comin11Serena Pillozzi12Lorenzo Antonuzzo13Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, ItalyClinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyClinical Oncology Unit, Careggi University Hospital, Florence, ItalyClinical Oncology Unit, Careggi University Hospital, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, Italy; Thoracic Surgery Unit, Careggi University Hospital, Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, Italy; Section of Surgery, Histopathology and Molecular Pathology, University of Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, Italy; Corresponding author at: Serena Pillozzi, PhD, Medical Oncology Unit, Careggi University Hospital, Largo Brambilla, 3 - 50134, Florence, Italy.Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Italy; Medical Oncology Unit, Careggi University Hospital, Florence, ItalyObjectives: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in non-small cell lung cancer (NSCLC) treatment. We investigated absolute eosinophil count (AEC) as a predictor of clinical outcomes and toxicity in NSCLC patients receiving ICIs. Materials and Methods: AEC was retrospectively collected at baseline and during treatment from 158 advanced NSCLC patients treated with single agent anti-PD1/anti-PDL1 monoclonal antibody in first or subsequent line of therapy at Medical Oncology Unit, Careggi University Hospital, Florence (Italy), between January 2016 to October 2020. Results: We found a significant association between high baseline AEC (≥130/μL) and better clinical outcomes. The response rates were 64.4% and 35.6% for patients with high and low AEC, respectively (p = 0.009). The high-AEC group showed a significantly longer PFS and OS than the low-AEC group (mPFS = 7.0 months, 95% CI 5.0–10.0 vs 2.5 months, 95% CI 2.0–4.0, p = 0.007 and mOS = 9.0 months, CI 95% 7.0–15.0 vs 5.5 months, 95% CI 4.0–8.0, p = 0.009, respectively). An increased risk of immune-related adverse events (irAEs) was reported in the high-AEC group (p = 0.133). IrAEs resulted an independent prognostic factor for both better outcomes (mPFS = 8.0 months, 95% CI 7.0–12.0 vs 2.0 months, 95% CI 2.0–3.0, p<0.001; mOS = 13.0 months 95% CI 9.0–19.0 vs 4.0 months 95% CI 3.0–6–0, p<0.001) and response to ICIs (response rate = 33.8% vs 14.9%, disease control rate = 72.0% vs 32.1%, p<0.001). Conclusion: High baseline AEC value (≥130/μL) is a predictive biomarker of clinical benefit and irAEs occurrence in NSCLC patients treated with ICIs.http://www.sciencedirect.com/science/article/pii/S2468294222000934Non-small cell lung cancerImmunotherapyEosinophilsAbsolute eosinophil countBiomarker |
| spellingShingle | Enrico Caliman Sara Fancelli Carlotta Ottanelli Francesca Mazzoni Luca Paglialunga Daniele Lavacchi Marta Rita Gatta Michelet Elisa Giommoni Brunella Napolitano Federico Scolari Luca Voltolini Camilla Eva Comin Serena Pillozzi Lorenzo Antonuzzo Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy Cancer Treatment and Research Communications Non-small cell lung cancer Immunotherapy Eosinophils Absolute eosinophil count Biomarker |
| title | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy |
| title_full | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy |
| title_fullStr | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy |
| title_full_unstemmed | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy |
| title_short | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy |
| title_sort | absolute eosinophil count predicts clinical outcomes and toxicity in non small cell lung cancer patients treated with immunotherapy |
| topic | Non-small cell lung cancer Immunotherapy Eosinophils Absolute eosinophil count Biomarker |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222000934 |
| work_keys_str_mv | AT enricocaliman absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT sarafancelli absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT carlottaottanelli absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT francescamazzoni absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT lucapaglialunga absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT danielelavacchi absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT martaritagattamichelet absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT elisagiommoni absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT brunellanapolitano absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT federicoscolari absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT lucavoltolini absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT camillaevacomin absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT serenapillozzi absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy AT lorenzoantonuzzo absoluteeosinophilcountpredictsclinicaloutcomesandtoxicityinnonsmallcelllungcancerpatientstreatedwithimmunotherapy |